NEW BRUNSWICK, N.J.—Johnson & Johnson (NYSE: JNJ) announced that its sales in the second quarter of 2023 increased 6.3 percent over the same period last year to $25.5 billion with operational growth of 7.5 percent and adjusted operational growth of 6.2 percent. The increase was bolstered by strong sales growth from the company’s MedTech business. Net income for the quarter was $5.14 billion compared with $4.8 billion for the same period in 2022. The company also announced that it is increasing 2023 full-year guidance.

“Our robust performance in the second quarter and first half of 2023 is a testament to the hard work and commitment of our colleagues around the world,” said Joaquin Duato, chairman of the board and chief executive officer at Johnson and Johnson. “We are entering the back half of the year from a position of strength with numerous catalysts, including becoming a two-sector company focused on pharmaceutical and MedTech innovation.”

MedTech revenue came in at $7.8 billion, with worldwide adjusted operational sales growing 9.9 percent, driven primarily by electrophysiology products in interventional solutions, trauma in orthopedics, wound closure products in general surgery, biosurgery in advanced surgery, and contact lenses in vision. MedTech worldwide operational sales grew 14.7 percent, with the acquisition of Abiomed contributing 4.8 percent.

Within the MedTech segment, vision sales increased 5.4 percent worldwide in the second quarter (6.6 percent in the U.S.) and sales of contact lenses grew 5.1 percent, led by a 9.1 percent increase in the U.S.

Pharmaceutical revenue was $13.7 billion and worldwide adjusted operational sales grew 3.9 percent. Excluding the COVID-19 vaccine, adjusted operational sales grew 6.2 percent. Consumer health ($4.0 billion) worldwide adjusted operational sales increased 7.7 percent, largely driven by over-the-counter (OTC) products.

Regionally, sales in the U.S. increased 10.2 percent and 6.3 percent worldwide.

Johnson and Johnson is now forecasting full-year sales of $98.80 billion to $99.80 billion, about $1 billion higher than the guidance provided in April.